Dr. McDermott on Lessons From the IMmotion150 Trial in RCC

David F. McDermott, MD
Published: Wednesday, Mar 08, 2017



David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

As the first large-scale look at atezolizumab in this setting, IMmotion150 will impact how immune agents are used in the first and second line, says McDermott.

In addition to aiding in design for a phase III trial, the results of IMmotion150 suggest that atezolizumab may be effective in the adjuvant setting.
 
SELECTED
LANGUAGE


David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

As the first large-scale look at atezolizumab in this setting, IMmotion150 will impact how immune agents are used in the first and second line, says McDermott.

In addition to aiding in design for a phase III trial, the results of IMmotion150 suggest that atezolizumab may be effective in the adjuvant setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x